These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3144529)

  • 1. Comparative studies of fleroxacin and ofloxacin in experimental pyelonephritis.
    Ritzerfeld W
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():119-22. PubMed ID: 3144529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures.
    Bauernfeind A; Eberlein E; Hörl G
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():81-9. PubMed ID: 3144553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of quinolones against slowly growing bacteria.
    Dalhoff A; Matutat S; Ullmann U
    Chemotherapy; 1995; 41(2):92-9. PubMed ID: 7758362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone.
    Aoyama H; Inoue M; Mitsuhashi S
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():99-114. PubMed ID: 2849604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro studies of fleroxacin (Ro 23-6240), a new trifluorinated quinolone derivative.
    Digranes A; Benonisen E; Salveson A; Zahm F
    Chemotherapy; 1988; 34(5):401-10. PubMed ID: 3141116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of fleroxacin.
    Georgopoulos A; Breyer S; Georgopoulos M; Mailer H; Graninger W
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():25-9. PubMed ID: 3144544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Activity of 5 fluoroquinolones on hospital Gram-negative bacilli with different sensitivities to pefloxacin].
    Aubert G; Puech C; Lucht F; Loboguerrero M; Denis M; Dorche G
    Pathol Biol (Paris); 1989 Oct; 37(8):881-7. PubMed ID: 2515519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB; Swanson RN
    Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
    Beskid G; Prosser BL
    Am J Med; 1993 Mar; 94(3A):2S-8S. PubMed ID: 8383919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sub-minimal inhibitory concentrations of ciprofloxacin and fleroxacin on the bacterial capsular antigen and opsonophagocytosis by human polymorphonuclear leukocytes.
    Keller N; Raponi G; Hoepelman IM; Overbeek BP; Rozenberg-Arska M; Verhoef J
    Zentralbl Bakteriol; 1991 Jan; 274(4):519-26. PubMed ID: 1907453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of ofloxacin and four other new quinoline-carboxylic acids against Chlamydia trachomatis.
    Nagayama A; Nakao T; Taen H
    Antimicrob Agents Chemother; 1988 Nov; 32(11):1735-7. PubMed ID: 3150916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis.
    Akaniro JC; Vidaurre CE; Stutman HR; Marks MI
    Antimicrob Agents Chemother; 1990 Oct; 34(10):1880-4. PubMed ID: 2127170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fleroxacin combined with rifampin.
    Zhang YX; Neu HC
    Diagn Microbiol Infect Dis; 1991; 14(1):23-7. PubMed ID: 1901534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of fleroxacin, two other quinolones and three board-spectrum beta-lactams using the E-Test.
    Sobottka I; Neumann S; Laufs R
    Chemotherapy; 1994; 40(5):293-8. PubMed ID: 7956451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro susceptibility of staphylococci to fleroxacin in comparison with six other quinolones.
    Pohlod DJ; Saravolatz LD; Somerville MM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():35-41. PubMed ID: 3144547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin.
    Appelbaum PC; Spangler SK; Tamarree T
    Chemotherapy; 1988; 34(1):40-5. PubMed ID: 3127127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria.
    Salfinger M; Hohl P; Kafader FM
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():55-63. PubMed ID: 3144550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between growth curves and killing curves of Escherichia coli in the presence of fleroxacin and ampicillin.
    Yourassowsky E; Van der Linden MP; Crokaert F
    Chemotherapy; 1989; 35(6):423-30. PubMed ID: 2515040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ABT-719, a 2-pyridone antimicrobial, against enterococci, Escherichia coli, and Pseudomonas aeruginosa in experimental murine pyelonephritis.
    Meulbroek JA; Oleksijew A; Tanaka SK; Alder JD
    J Antimicrob Chemother; 1996 Oct; 38(4):641-53. PubMed ID: 8937959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.